MAY 12, 2021
FDA Adds Warning to Package for Ophthalmic Drop Used to Treat Ptosis
Ophthalmologists who use the ophthalmic drop, Upneeq (oxymetazoline hydrochloride ophthalmic solution 0.1%), to treat ptosis will soon see a new package insert (PDF) that includes a warning about the potentially serious neurological and orbital conditions associated with ptosis.